Pathogenesis of group A streptococcal infections.

Anna Henningham, Timothy C. Barnett, Peter G. Maamary, Mark J. Walker

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


Group A Streptococcus (GAS; Streptococcus pyogenes) is a human pathogen which causes significant morbidity and mortality globally. GAS typically infects the throat and skin of the host, causing mild infections such as pharyngitis and impetigo, in addition to life threatening conditions including necrotizing fasciitis, streptococcal toxic shock syndrome (STSS), and bacteremia. Repeated infection with GAS may result in the non-suppurative sequelae, acute rheumatic fever, and acute glomerulonephritis. GAS remains sensitive to the antibiotic penicillin which can be administered as a means to treat infection or as prophylaxis. However, issues with patient compliance and a growing concern over the possible emergence of resistant GAS strains may limit the usefulness of antibiotics in the future. A vaccine capable of preventing GAS infection may be the only effective way to control and eliminate GAS infection and disease.

Original languageEnglish
Pages (from-to)329-342
Number of pages14
JournalDiscovery Medicine
Issue number72
Publication statusPublished - May 2012
Externally publishedYes


Dive into the research topics of 'Pathogenesis of group A streptococcal infections.'. Together they form a unique fingerprint.

Cite this